Analyst Price Targets — APGE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 13, 2026 12:35 pm | — | Truist Financial | $135.00 | $134.54 | TheFly | Apogee Therapeutics price target raised to $135 from $81 at Truist |
| June 24, 2026 1:33 pm | — | Stifel Nicolaus | $135.00 | $132.97 | TheFly | Apogee Therapeutics downgraded to Hold from Buy at Stifel |
| June 24, 2026 8:12 am | Joseph Catanzaro | Mizuho Securities | $135.00 | $132.88 | StreetInsider | Mizuho Downgrades Apogee Therapeutics Inc (APGE) to Neutral |
| June 23, 2026 10:49 am | — | RBC Capital | $135.00 | $132.55 | TheFly | Apogee Therapeutics downgraded to Sector Perform from Outperform at RBC Capital |
| June 23, 2026 9:21 am | — | UBS | $135.11 | $132.55 | TheFly | Apogee Therapeutics downgraded to Neutral from Buy at UBS |
| June 22, 2026 7:40 pm | David Hoang | Deutsche Bank | $135.00 | $132.55 | TheFly | Apogee Therapeutics downgraded to Hold from Buy at Deutsche Bank |
| June 22, 2026 3:54 pm | — | Craig-Hallum | $135.11 | $132.65 | TheFly | Apogee Therapeutics downgraded to Hold from Buy at Craig-Hallum |
| June 8, 2026 9:19 am | Brian Abrahams | RBC Capital | $97.00 | $86.92 | StreetInsider | Apogee Therapeutics Inc (APGE) PT Raised to $97 at RBC Capital |
| May 28, 2026 12:05 pm | — | Goldman Sachs | $89.00 | $77.50 | TheFly | Apogee Therapeutics moved to Neutral at Goldman Sachs |
| May 27, 2026 4:51 pm | Danielle Brill | Truist Financial | $81.00 | $78.07 | TheFly | Apogee Therapeutics price target lowered to $81 from $83 at Truist |
Latest News for APGE
Deutsche Bank AG acquired a new stake in Apogee Therapeutics Inc. (NASDAQ: APGE) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 98,979 shares of the company's stock, valued at approximately $13,137,000. Deutsche Bank AG owned approximately 0.16% of
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive 16-week Phase 2 APEX Part B induction dose optimization results support planned advancement of zumilokibart into Phase 3 development in moderate-to-severe atopic dermatitis this year SAN FRANCISCO and BOSTON, Aug. 10,…
Apogee Therapeutics Inc. (NASDAQ: APGE - Get Free Report) insider Carl Dambkowski sold 5,500 shares of Apogee Therapeutics stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $134.17, for a total value of $737,935.00. Following the transaction, the insider directly owned 168,498 shares of the company's stock, valued
California State Teachers Retirement System raised its stake in shares of Apogee Therapeutics Inc. (NASDAQ: APGE) by 24.1% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,161 shares of the company's stock after acquiring an additional 7,403
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for APGE.
U.S. House Trading
No House trades found for APGE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.